Haleon (NYSE:HLN) Sees Unusually-High Trading Volume - Should You Buy?

Key Points

• Haleon experienced unusually high trading activity, with about 7.5 million shares traded, although volume declined 20% from the prior session. Shares last traded at $9.255, below the previous close of $9.36.
• Analyst views are mixed, but the stock carries a “Moderate Buy” consensus rating: two analysts rate it Strong Buy, two Buy, four Hold and one Sell.
• Haleon has a $40.62 billion market capitalization and pays a dividend, while its shares trade below both the 50-day and 200-day moving averages. Institutional investors and hedge funds own 6.67% of the company.

Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) saw strong trading volume on Friday . Approximately 7,510,183 shares changed hands during trading, a decline of 20% from the previous session's volume of 9,395,404 shares.The stock last traded at $9.2550 and had previously closed at $9.36.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley restated an "overweight" rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a research note on Sunday, July 12th. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Haleon in a research note on Tuesday, August 11th. Weiss Ratings reissued a "hold (c)" rating on shares of Haleon in a report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Haleon in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy".

Haleon Price Performance

The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The stock has a fifty day simple moving average of $9.82 and a two-hundred day simple moving average of $9.64. The company has a market cap of $40.62 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.12.

Haleon Cuts Dividend

The firm also recently declared a dividend, which was paid on Thursday, September 17th. Investors of record on Friday, August 14th were paid a $0.0642 dividend. The ex-dividend date was Friday, August 14th. This represents a dividend yield of 132.0%. Haleon's payout ratio is 30.77%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Western Wealth Management LLC acquired a new stake in Haleon in the first quarter valued at $29,000. Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of Haleon by 402.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company's stock valued at $30,000 after purchasing an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company's stock valued at $58,000 after purchasing an additional 1,055 shares in the last quarter. Gryphon Financial Partners LLC acquired a new stake in shares of Haleon in the first quarter valued at about $101,000. Finally, NWF Advisory Services Inc. acquired a new stake in shares of Haleon in the first quarter valued at about $102,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK's consumer healthcare business and became an independent company in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.